4.4 Article

The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period

期刊

CLINICAL ENDOCRINOLOGY
卷 97, 期 6, 页码 773-782

出版社

WILEY
DOI: 10.1111/cen.14828

关键词

acromegaly; growth hormone; pituitary adenoma; pituitary endocrinology

资金

  1. Pfizer
  2. IPSEN

向作者/读者索取更多资源

This study investigated the prevalence and patient characteristics of acromegaly over time, as well as the impact of treatment changes on disease control. The study found that the prevalence of acromegaly has increased significantly, with a shift towards a milder clinical phenotype. Modern treatment approaches enable individualized treatment and disease control in the majority of patients with acromegaly.
Objective To study time-related changes in the prevalence and patient characteristics of acromegaly, as well as to assess the impact of changes in treatment on disease control. Methods A total of 107 patients with acromegaly were identified by healthcare registries and subsequently validated by patient chart review over a three-decade period (1992-2021). A systematic literature review focusing on the incidence and prevalence of acromegaly was performed identifying 31 studies. Results The prevalence of acromegaly significantly increased throughout the study period (R-2 = 0.94, p < .001) and was 122 cases/10(6) persons in 2021 whereas the annual incidence remained constant at 4.6 cases/10(6) persons. The age at the first sign of acromegaly and the age at diagnosis significantly increased during the study period, whereas growth hormone and insulin-like growth factor I decreased. Incidentalomas constituted 32% of all cases diagnosed with acromegaly in the last decade. Primary surgery was used in 93% of all cases, and repeated surgery decreased from 24% to 10% during the three decades. The use of first-generation somatostatin analogues (21%-48%) and second-line medical treatment (4%-20%) increased with a concomitant improvement of biochemical disease control (58%-91%). Conclusion The prevalence of acromegaly is higher than previously reported and the clinical presentation has shifted towards a milder phenotype. Modern treatment of acromegaly enables individualized treatment and disease control in the majority of patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据